Evonik is one of the world's leading specialty chemicals companies. Profitable growth and sustained value creation form the heart of the company´s strategy. Around 80% of the sales come from leading market positions, with plans to expand further. Evonik concentrates on high-growth megatrends, especially health, nutrition, resource efficiency and globalization. In 2013 Evonik’s roughly 33,000 employees generated sales of €12.71 billion and an operating result (adjusted EBITDA) of €2.0 billion. Around 76% of the sales are generated outside Germany, fact which strongly underlines the globality of the business. Innovation is a key driver for specialty chemicals. New products and solutions secure profitable growth for Evonik. They open up new business areas and strengthen the existing leading market and technology positions. Innovative strength and efficient R&D are already hallmarks of Evonik. The key growth fields include cosmetic additives, additives for food and animal feed, pharmaceuticals and biotechnology, oilfield chemicals, membranes, composites and electronic materials.

Link: www.evonik.de

Role in the project

EVO has a wide experience in genetics, biotechnology, pathway engineering, pathway characterization and biochemistry of several usual and unusual bacteria. Successfully established biotechnological processes were scaled up to a pilot plant. The company develops biotechnological processes for substitution or improvement (selectivity, resource efficiency, etc.) of known chemical processes and establishes new processes  for new products in order to capture promising markets.

EVO will undertake the validation of successfully accomplished preliminary studies regarding key products and the scale up of successfully validated processes deriving from the project.

Contributors to CARBAZYMES

 Ms. Anja Thiessenhusen

 Project Manager

 Dr. Stefan Gilch

 Senior Scientist

 Dr. Thomas Buelter

 Senior Scientist

 Mr. Simon Beck



Go to top